Liraglutide: Dosage, Protocol, and Research Guide
GLP-1 receptor agonist for weight management and type 2 diabetes control
Mechanism
97% homologous to human GLP-1, with modifications for extended half-life. Increases insulin secretion, suppresses glucagon, delays gastric emptying, and reduces appetite through hypothalamic pathways.
Protocol at a glance
| Starting dose | 0.6mg |
|---|---|
| Maintenance dose | 1.2-3.0mg |
| Maximum dose | 3.0mg |
| Frequency | Once daily |
| Typical duration | Ongoing therapy |
| Route | Subcutaneous |
| Injection site | Abdomen, thigh, or upper arm |
| Timing | Any time of day, with or without food |
Titration schedule
| Week | Dose | Notes |
|---|---|---|
| 1 | 0.6mg | Initial dose for 1 week |
| 2 | 1.2mg | Standard maintenance dose |
| 3 | 1.8mg | If additional effect needed |
| 4 | 3.0mg | Maximum dose for weight loss |
Side effects
- Nausea
- Vomiting
- Diarrhea
- Headache
- Hypoglycemia
Contraindications
- Personal or family history of medullary thyroid carcinoma
- Multiple endocrine neoplasia syndrome type 2 (MEN 2)
- Serious hypersensitivity to the drug or its components
Protocol notes
- Boxed warning: causes thyroid C-cell tumors in rodents; whether it does so in humans has not been determined
- Warnings rather than contraindications: pancreatitis (stop if suspected) and type 1 diabetes (not indicated)
- Take at same time each day
- Rotate injection sites
- Monitor for hypoglycemia if on other diabetes medications
- Saxenda brand for weight loss, Victoza for diabetes
Research references
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management · PMID 26132939
- Liraglutide for weight management: a critical review of the evidence · PMID 28392927
Frequently asked questions
What is Liraglutide and how does it work?
Liraglutide is a GLP-1 receptor agonist that is 97% homologous to human glucagon-like peptide-1, a hormone critical to glucose regulation and appetite control. Liraglutide includes chemical modifications that extend its half-life, enabling once-daily dosing. It works through multiple mechanisms: increasing insulin secretion in response to high blood glucose, suppressing glucagon release, delaying gastric emptying to promote fullness, and reducing appetite through hypothalamic pathways. This multi-target approach makes it effective for both weight management and glucose control.
What is the standard dosing protocol for Liraglutide?
Liraglutide therapy begins at 0.6mg once daily and is titrated to a maintenance dose of 1.2–3.0mg once daily, with a maximum dose of 3.0mg daily. It is administered via subcutaneous injection to the abdomen, thigh, or upper arm. Liraglutide can be injected at any time of day with or without food, though consistent timing is recommended. Injection sites should be rotated to minimize local tissue complications.
What are the common side effects of Liraglutide?
Common side effects include nausea, vomiting, diarrhea, and headache, with gastrointestinal effects often diminishing over time as the body adjusts. Hypoglycemia is a concern, particularly if Liraglutide is used with other diabetes medications—patients in this situation should monitor blood glucose regularly. Individual responses vary; some experience significant side effects while others tolerate the medication well.
Who should not use Liraglutide?
Liraglutide is contraindicated with a personal or family history of medullary thyroid carcinoma, MEN 2, or a prior serious hypersensitivity reaction to it, and it carries a boxed warning about thyroid C-cell tumors seen in rodents. It is not indicated for type 1 diabetes, and pancreatitis has been reported. Medical evaluation is essential before use to determine individual suitability.
Can Liraglutide be cycled or stacked with other peptides?
Research on Liraglutide cycling and stacking remains limited. Combining Liraglutide with other medications—especially diabetes agents—requires careful medical supervision due to hypoglycemia risk. The safety and efficacy of such combinations have not been systematically established in available literature. Any consideration of cycling or combining Liraglutide must be discussed with a licensed healthcare provider.
What lab markers should be monitored while using Liraglutide?
Blood glucose monitoring is essential, particularly for those taking concurrent diabetes medications. Baseline and periodic assessment of kidney function and pancreatic enzymes may be prudent given that pancreatitis has been reported. Regular medical follow-up allows for dose adjustments and early detection of any adverse effects.
Is Liraglutide legal or FDA-approved for human use?
Yes. Liraglutide is FDA-approved and prescription-only in the US: as Victoza for type 2 diabetes and as Saxenda for chronic weight management. Use outside those indications should only happen under a licensed physician's care.
What is the difference between Saxenda and Victoza Liraglutide formulations?
Saxenda and Victoza are both brand names for the same active ingredient, Liraglutide, but differ in their indicated use. Saxenda is formulated and marketed for weight management, while Victoza is approved for type 2 diabetes control. Both contain identical Liraglutide and operate through the same GLP-1 mechanism. The choice depends on the clinical indication and is determined by a healthcare provider.
Compare
Related peptides
More GLP-1 & Weight Loss peptides · All peptide guides · All comparisons · Free dose calculator
Educational reference only — not medical advice. Work with a qualified clinician.